General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Alnylam(MODEST), Amgen Inc.(SIGNIFICANT), Applied Therapeutics(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Cytokinetics(MODEST), Eli Lilly and Company(MODEST), Esperion Therapeutics(MODEST), Lexicon(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Pharmacosmos(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT), Vifor Pharma(SIGNIFICANT), 35Pharma(MODEST), Dexcom(MODEST), Pfizer Inc(MODEST), scPharmaceuticals(MODEST), Structure Therapeutics(MODEST), Youngene Therapeutics(MODEST), Arrowhead Pharmaceuticals(MODEST), Regeneron(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Artera Health(MODEST), Saghmos Therapeutics(MODEST) RESEARCH/RESEARCH GRANTS: Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Pfizer Inc(SIGNIFICANT)

View Full Disclosure